Wealth Alliance Has $204,000 Stake in Haleon plc (NYSE:HLN)

Wealth Alliance lowered its stake in Haleon plc (NYSE:HLN) by 36.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 21,374 shares of the company’s stock after selling 12,365 shares during the period. Wealth Alliance’s holdings in Haleon were worth $204,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Creative Planning increased its stake in shares of Haleon by 15.2% in the 3rd quarter. Creative Planning now owns 285,227 shares of the company’s stock valued at $3,018,000 after buying an additional 37,566 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in Haleon by 44.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 25,560 shares of the company’s stock valued at $270,000 after acquiring an additional 7,856 shares during the last quarter. Sequoia Financial Advisors LLC increased its position in Haleon by 2.0% in the third quarter. Sequoia Financial Advisors LLC now owns 83,589 shares of the company’s stock worth $881,000 after purchasing an additional 1,646 shares during the period. International Assets Investment Management LLC bought a new stake in Haleon during the 3rd quarter worth about $3,700,000. Finally, Ballentine Partners LLC lifted its position in Haleon by 53.1% during the 3rd quarter. Ballentine Partners LLC now owns 22,831 shares of the company’s stock valued at $242,000 after purchasing an additional 7,918 shares during the period. Institutional investors and hedge funds own 6.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Sanford C. Bernstein lowered shares of Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.95.

Haleon Price Performance

Shares of HLN opened at $10.08 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The stock has a market cap of $45.61 billion, a P/E ratio of 29.63, a price-to-earnings-growth ratio of 2.82 and a beta of 0.28. The stock’s 50-day moving average price is $9.56 and its two-hundred day moving average price is $9.82. Haleon plc has a 1 year low of $7.89 and a 1 year high of $10.80.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.